SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)

Clostridioides difficile infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20–25% of patients with a primary infection experience a recurrence, and the risk of recurrence incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Sahil, Sims, Matthew, Louie, Thomas J., Fischer, Monika, LaPlante, Kerry, Allegretti, Jessica, Hasson, Brooke R., Fonte, Allyson T., McChalicher, Christopher, Ege, David S., Bryant, Jessica A., Straub, Timothy J., Ford, Christopher B., Henn, Matthew R., Wang, Elaine E. L., von Moltke, Lisa, Wilcox, Mark H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495252/
https://www.ncbi.nlm.nih.gov/pubmed/36140013
http://dx.doi.org/10.3390/antibiotics11091234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495252/
https://www.ncbi.nlm.nih.gov/pubmed/36140013
http://dx.doi.org/10.3390/antibiotics11091234

Ejemplares similares